Ledipasvir D tartrate
| Product Name | Ledipasvir D tartrate |
|---|---|
| Alternate Names | Ledipasvir Impurities, Impurities of Ledipasvir |
| CAT No. | CS-O-16784 |
| CAS No. | 1502654-87-6 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 1039.09 g/mol |
| Mol. For. | C₅₃H₆₀F₂N₈O₁₂ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ledipasvir |
| Purity | Not less than 95 % |
| Therapeutic | Antiretroviral / Anti-HIV |
| Canonical Smiles | CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC.C(C(C(=O)O)O)(C(=O)O)O |
| InchIKey | ZQVLPYMRXLPMDX-KEAIDYLOSA-N |
| Inchl | InChI=1S/C49H54F2N8O6.C4H6O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6;5-1(3(7)8)2(6)4(9)10/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63);1-2,5-6H,(H,7,8)(H,9,10)/t29-,30+,38-,39-,40-,41-;1-,2-/m00/s1 |
| IUPAC | (2S,3S)-2,3-dihydroxybutanedioic acid;methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Ledipasvir D tartrate is a medication used for the treatment of chronic hepatitis C virus (HCV) infection. It is a fixed-dose combination drug that contains ledipasvir and sofosbuvir, which are both direct-acting antiviral agents (DAAs). Ledipasvir works by inhibiting the function of the NS5A protein, an essential component of the HCV replication complex. Sofosbuvir, on the other hand, inhibits the function of the NS5B RNA-dependent RNA polymerase, which is also involved in HCV replication. Together, these drugs help to prevent the replication of the virus and reduce its levels in the body.
Ledipasvir D tartrate is typically administered orally once daily, with or without food. The dosage and duration of treatment depend on various factors such as the genotype of the virus, the patient's medical history, and the presence of any liver damage. The drug is usually taken for 8 to 12 weeks, and its effectiveness is assessed through regular blood tests.
Regarding its chemical information, ledipasvir D tartrate has a molecular formula of C49H54F2N8O8S2C4H6O6 and a molecular weight of 1199.3 g/mol. It is a crystalline solid that is soluble in water and organic solvents such as methanol and ethanol. The drug is metabolized in the liver and excreted in the feces and urine. It is important to note that ledipasvir D tartrate may interact with other medications, so it is essential to inform the healthcare provider of any other drugs being taken.
Get an Instant Quote
Related Compounds
Ledipasvir Chiral Impurity 6 | Ledipasvir Chiral Impurity 3 | Ledipasvir Chiral Impurity 4 | Ledipasvir Impurity-6 | Ledipasvir Chiral Impurity 5 | Ledipasvir Impurity-11 | Ledipasvir Diastereomer-1 | Ledipasvir Impurity-4 | Ledipasvir Diastereomer-3 | Ledipasvir Impurity-7 | Ledipasvir Impurity-5 | Ledipasvir Chiral Impurity 7 | Ledipasvir Chiral Impurity 2 | Ledipasvir Impurity-9 | Ledipasvir Chiral Impurity 1 | Ledipasvir Impurity-10 | Ledipasvir Impurity-12 | Ledipasvir Impurity-2 | N(azanorbornyl)-Des(methoxycarbonyl)valino Ledipasvir | Ledipasvir Impurity-3 | Ledipasvir Impurity-8 |